[go: up one dir, main page]

WO2002008281A3 - Proteine bstp-cad et reactifs associes et methodes d'utilisation - Google Patents

Proteine bstp-cad et reactifs associes et methodes d'utilisation Download PDF

Info

Publication number
WO2002008281A3
WO2002008281A3 PCT/US2001/023566 US0123566W WO0208281A3 WO 2002008281 A3 WO2002008281 A3 WO 2002008281A3 US 0123566 W US0123566 W US 0123566W WO 0208281 A3 WO0208281 A3 WO 0208281A3
Authority
WO
WIPO (PCT)
Prior art keywords
bstp
cad
provides
methods
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/023566
Other languages
English (en)
Other versions
WO2002008281A2 (fr
Inventor
David Botstein
Patrick O Brown
Chuck Perou
Douglas Ross
Rob Seitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Genomics Inc
Leland Stanford Junior University
Original Assignee
Applied Genomics Inc
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Genomics Inc, Leland Stanford Junior University filed Critical Applied Genomics Inc
Priority to AU2001277200A priority Critical patent/AU2001277200A1/en
Publication of WO2002008281A2 publication Critical patent/WO2002008281A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002008281A3 publication Critical patent/WO2002008281A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un polypeptide (BSTP-CAD), des polypeptides associés, des fragments et des variantes de ceux-ci, et des polynucléotides identifiant et codant pour BSTP-CAD et les autres polypeptides. L'invention concerne également des vecteurs d'expression, des cellules hôte, des anticorps, des agonistes et des antagonistes. De plus, l'invention concerne des méthodes de traitement ou de prévention des troubles associés à la prolifération cellulaire, en particulier le cancer du sein, consistant à administrer une composition pharmaceutique comprenant un polypeptide, un polynucléotide, ou un anticorps de l'invention. L'invention concerne également des méthodes de classification des maladies, en particulier du cancer du sein, par détection de l'expression de BSTP-CAD ou d'un polynucléotide codant pour BSTP-CAD, et de génération d'informations diagnostiques, pronostiques, et/ou prédictives sur un patient, basées sur la détection et/ou la mesure de BSTP-CAD ou d'un polynucléotide codant pour BSTP-CAD.
PCT/US2001/023566 2000-07-26 2001-07-26 Proteine bstp-cad et reactifs associes et methodes d'utilisation Ceased WO2002008281A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001277200A AU2001277200A1 (en) 2000-07-26 2001-07-26 Bstp-cad protein and related reagents and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22096700P 2000-07-26 2000-07-26
US60/220,967 2000-07-26
US26783301P 2001-02-09 2001-02-09
US60/267,833 2001-02-09

Publications (2)

Publication Number Publication Date
WO2002008281A2 WO2002008281A2 (fr) 2002-01-31
WO2002008281A3 true WO2002008281A3 (fr) 2003-07-03

Family

ID=26915370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/023566 Ceased WO2002008281A2 (fr) 2000-07-26 2001-07-26 Proteine bstp-cad et reactifs associes et methodes d'utilisation

Country Status (2)

Country Link
AU (1) AU2001277200A1 (fr)
WO (1) WO2002008281A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044063A2 (fr) * 1998-02-25 1999-09-02 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Micro-arrangements de tissus tumoraux permettant une definition de profil moleculaire rapide
US5997866A (en) * 1996-11-27 1999-12-07 Johnson; Keith R. Panel of antibodies for detecting cadherins, catenins and plaque proteins in tissues and method of using the panel
WO2001055368A1 (fr) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997866A (en) * 1996-11-27 1999-12-07 Johnson; Keith R. Panel of antibodies for detecting cadherins, catenins and plaque proteins in tissues and method of using the panel
WO1999044063A2 (fr) * 1998-02-25 1999-09-02 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Micro-arrangements de tissus tumoraux permettant une definition de profil moleculaire rapide
WO2001055368A1 (fr) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BERX GEERT ET AL: "E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 14, no. 24, 1995, pages 6107 - 6115, XP002204447, ISSN: 0261-4189 *
DATABASE EBI [online] EMBL, Hinxton, UK; 30 July 1995 (1995-07-30), BOUILLARD, F.: "EST25e12 WATM1 Homo sapiens cDNA clone 25e12, mRNA sequence.", XP002204452, Database accession no. HS479180 *
DATABASE EMBL [online] EBI, Hinxton, UK; 15 June 1998 (1998-06-15), SULSTON, J.E. AND WATERSTON, R.: "Homo sapiens PAC clone RP4-568B10 from 7q31.1-q31.2, complete sequence.", XP002204449, Database accession no. AC004836 *
DATABASE EMBL [online] EBI, Hinxton, UK; 4 July 1999 (1999-07-04), "oo30g12.y5 NCI_CGAP_Lu5 Homo sapiens cDNA clone IMAGE:1567750 5', mRNA sequence", XP002204451, Database accession no. AI793167 *
DATABASE GENSEQ [online] Derwent; 4 December 2001 (2001-12-04), ROSEN ET AL.: "Human cDNA encoding a novel extracellular matrix protein, Seq ID No 189", XP002204454, Database accession no. AAS31375 *
DATABASE GENSEQ [online] Derwent; ROSEN ET AL.: "Human cDNA encoding a novel extracellular matrix protein, Seq ID No 28", XP002204453, Database accession no. AAS31214 *
MARTIN K J ET AL: "LINKING GENE EXPRESSION PATTERNS TO THERAPEUTIC GROUPS IN BREAST CANCER", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 8, 15 April 2000 (2000-04-15), pages 2232 - 2238, XP001026395, ISSN: 0008-5472 *
MENDOZA L G ET AL: "HIGH-THROUGHPUT MICROARRAY-BASED ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)", BIOTECHNIQUES, EATON PUBLISHING, NATICK, US, vol. 27, no. 4, October 1999 (1999-10-01), pages 778,780,782 - 786,788, XP000992893, ISSN: 0736-6205 *
NOLLET FRIEDEL ET AL: "Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members.", JOURNAL OF MOLECULAR BIOLOGY, vol. 299, no. 3, 2000, pages 551 - 572, XP002204446, ISSN: 0022-2836 *
PEROU CHARLES M ET AL: "Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 16, 3 August 1999 (1999-08-03), Aug. 3, 1999, pages 9212 - 9217, XP002204448, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU2001277200A1 (en) 2002-02-05
WO2002008281A2 (fr) 2002-01-31

Similar Documents

Publication Publication Date Title
WO2002008262A3 (fr) Proteines bstp-5 et reactifs apparentes, et leurs procedes d'utilisation
WO2002008260A3 (fr) Proteine bstp-ecg1 et reactifs associes et procedes d'utilisation de ceux-ci
Hondermarck et al. Proteomics of breast cancer for marker discovery and signal pathway profiling
Dahlmann Mammalian proteasome subtypes: Their diversity in structure and function
CA2906965C (fr) Dosage srm afin d'indiquer une therapie contre le cancer
KR20200028510A (ko) 화학요법 표적에 대한 srm 검정
WO2002032953A3 (fr) Proteine plasmatique a2 associee a la grossesse (papp-a2)
WO2000015793A3 (fr) Proteines gpcr humaines
Petri et al. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology
WO2002008282A3 (fr) Proteine bstp-ras/rerg et reactifs apparentes, procedes d'utilisation de ces derniers
US9766246B2 (en) SRM/MRM assay for subtyping lung histology
Ivancic et al. Candidate serum biomarkers for early intestinal cancer using 15N metabolic labeling and quantitative proteomics in the Apc Min/+ mouse
Syrjänen et al. Expression of cancer‐related carbonic anhydrases IX and XII in normal skin and skin neoplasms
Hong et al. Identification of a specific vimentin isoform that induces an antibody response in pancreatic cancer
Fernández-Grijalva et al. Alpha 2HS-glycoprotein, a tumor-associated antigen (TAA) detected in Mexican patients with early-stage breast cancer
Ardito et al. Novel possibilities in the study of the salivary proteomic profile using SELDI-TOF/MS technology
AU2015203904A1 (en) SRM assay for PD-L1
WO2005103719A3 (fr) Utilisation de motif proteomique de plasma aux fins de diagnostic, classification, prevision de reponse a un traitement et un comportement clinique, stratification de traitement et surveillance de la maladie dans le cas de malignites hematologiques
EA200000845A1 (ru) Ген, кодирующий новый маркер рака
Reddy et al. Amino acid profile of saliva from patients with oral squamous cell carcinoma using high performance liquid chromatography
EP1136547A3 (fr) Polypeptides Adamts, acides nucléiques codant pour ces polypeptides et leurs utilisations
EP1560025A3 (fr) Marquers specifiques pour diabète
Bajorath et al. Molecular model of the extracellular lectin-like domain in CD69.
WO2002008281A3 (fr) Proteine bstp-cad et reactifs associes et methodes d'utilisation
WO1999061614A3 (fr) Proteines socs humaines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP